Section Arrow
Quote
ARVN.NASDAQ
- Arvinas
Quotes are at least 15-min delayed:2026/04/01 06:45 EDT
Pre Market
Last
 10.77
+0.17 (+1.60%)
Bid
10.65
Ask
10.8
High 10.95 
Low 10.05 
Volume 4.78K 
Regular Hours (Closed)
Last
 10.6
+0.42 (+4.13%)
Day High 
10.85 
Prev. Close
10.18 
1-M High
14.51 
Volume 
1.14M 
Bid
10.65
Ask
10.8
Day Low
10.26 
Open
10.26 
1-M Low
9.9628 
Market Cap 
651.12M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 10.77 
20-SMA 11.99 
50-SMA 12.5 
52-W High 14.51 
52-W Low 5.9 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.14/-3.14
Enterprise Value
658.32M
Balance Sheet
Book Value Per Share
6.78
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
262.60M
Operating Revenue Per Share
2.49
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
VRAXVirax Biolabs Group Limited0.2199+0.0574+35.32%-- 
Pre Market 0.19 -0.0299 -13.60%
APLSApellis Pharmaceuticals40.23+23.14+135.40%94.94PE
Pre Market 40.43 +0.2 +0.50%
IOBTIO Biotech0.0587-0.1137-65.95%-- 
Pre Market 0.0498 -0.0089 -15.16%
ITRMIterum Therapeutics plc0.03-0.0404-57.39%-- 
Pre Market -- -- --
ELABPmgc Holdings Inc5.99+2.43+68.26%0PE
Pre Market 7.7229 +1.7329 +28.93%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to targetcertain harmful proteins causing oncology and neurology-related diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.